STAT3 blockade enhances the efficacy of conventional chemotherapeutic agents by eradicating head neck stemloid cancer cell

被引:39
作者
Bu, Lin-Lin [1 ,2 ,3 ]
Zhao, Zhi-Li [1 ,2 ]
Liu, Jian-Feng [1 ,2 ]
Ma, Si-Rui [1 ,2 ]
Huang, Cong-Fa [1 ,2 ]
Liu, Bing [1 ,2 ,3 ]
Zhang, Wen-Feng [1 ,2 ,3 ]
Sun, Zhi-Jun [1 ,2 ,3 ]
机构
[1] Minist Educ, State Key Lab Breeding Base Basic Sci Stomatol, Wuhan, Peoples R China
[2] Minist Educ, Key Lab Oral Biomed, Wuhan, Peoples R China
[3] Wuhan Univ, Dept Oral Maxillofacial Head Neck Oncol, Sch & Hosp Stomatol, Wuhan 430072, Peoples R China
基金
中国国家自然科学基金;
关键词
STAT3; head neck squamous cell carcinoma; cancer stem cell; S3I-201; chemotherapy; DRUG-RESISTANCE; DECOY OLIGONUCLEOTIDE; SIGNAL TRANSDUCERS; ANTITUMOR EFFICACY; GENE-EXPRESSION; SIDE POPULATION; ACTIVATION; INHIBITION; CISPLATIN; TRANSCRIPTION;
D O I
10.18632/oncotarget.5986
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Signaling transducer and activator 3 (STAT3) and cancer stem cells (CSCs) have garnered huge attention as a therapeutic focus, based on evidence that they may represent an etiologic root of tumor initiation and radio-chemoresistance. Here, we investigated the high phosphorylation status of STAT3 (p-STAT3) and its correlation with self-renewal markers in head neck squamous cell carcinoma (HNSCC). Overexpression of p-STAT3 was found to have increased in post chemotherapy HNSCC tissue. We showed that blockade of p-STAT3 eliminated both bulk tumor and side population (SP) cells with characteristics of CSCs in vitro. Inhibition of p-STAT3 using small molecule S3I-201 significantly delayed tumorigenesis of spontaneous HNSCC in mice. Combining blockade of p-STAT3 with cytotoxic drugs cisplatin, docetaxel, 5-fluorouracil (TPF) enhanced the antitumor effect in vitro and in vivo with decreased tumor sphere formation and SP cells. Taken together, our results advocate blockade of p-STAT3 in combination with conventional chemotherapeutic drugs enhance efficacy by improving CSCs eradication in HNSCC.
引用
收藏
页码:41944 / 41958
页数:15
相关论文
共 53 条
[1]   Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancer stem-like cells derived from recurrent glioblastoma [J].
Ashizawa, Tadashi ;
Miyata, Haruo ;
Iizuka, Akira ;
Komiyama, Masaru ;
Oshita, Chie ;
Kume, Akiko ;
Nogami, Masahiro ;
Yagoto, Mika ;
Ito, Ichiro ;
Oishi, Takuma ;
Watanabe, Reiko ;
Mitsuya, Koichi ;
Matsuno, Kenji ;
Furuya, Toshio ;
Okawara, Tadashi ;
Otsuka, Masami ;
Ogo, Naohisa ;
Asai, Akira ;
Nakasu, Yoko ;
Yamaguchi, Ken ;
Akiyama, Yasuto .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2013, 43 (01) :219-227
[2]   Cancer stem cell and cancer stemloids [J].
Blagosklonny, Mikhail V. .
CANCER BIOLOGY & THERAPY, 2007, 6 (11) :1684-1690
[3]  
Blagosklonny MV, 2014, CANCER BIOL THER, V6, P1684
[4]   The side population of ovarian cancer cells defines a heterogeneous compartment exhibiting stem cell characteristics [J].
Boesch, Maximilian ;
Zeimet, Alain G. ;
Reimer, Daniel ;
Schmidt, Stefan ;
Gastl, Guenther ;
Parson, Walther ;
Spoeck, Franziska ;
Hatina, Jiri ;
Wolf, Dominik ;
Sopper, Sieghart .
ONCOTARGET, 2014, 5 (16) :7027-7039
[5]   Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells [J].
Chiu, Huan-Chih ;
Chou, Ding-Li ;
Huang, Chin-Ting ;
Lin, Wen-Hsing ;
Lien, Tzu-Wen ;
Yen, Kuei-Jung ;
Hsu, John T. -A. .
BIOCHEMICAL PHARMACOLOGY, 2011, 81 (11) :1263-1270
[6]   The cancer stem cell: premises, promises and challenges [J].
Clevers, Hans .
NATURE MEDICINE, 2011, 17 (03) :313-319
[7]   Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms [J].
Dai, Y ;
Rahmani, M ;
Pei, XY ;
Dent, P ;
Grant, S .
BLOOD, 2004, 104 (02) :509-518
[8]  
Demaria M, 2012, ONCOTARGET, V3, P359
[9]   Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer [J].
Duan, Zhenfeng ;
Foster, Rosemary ;
Bell, Debra A. ;
Mahoney, Jennifer ;
Wolak, Kathryn ;
Vaidya, Ami ;
Hampel, Constanze ;
Lee, Hang ;
Seiden, Michael V. .
CLINICAL CANCER RESEARCH, 2006, 12 (17) :5055-5063
[10]   Polymer conjugates as anticancer nanomedicines [J].
Duncan, Ruth .
NATURE REVIEWS CANCER, 2006, 6 (09) :688-701